Therapeutic antibodies are drugs which are highly specific, attacking only the targeted cells. They are used in treatment of several diseases, including cardiovascular diseases, autoimmune disorders, cancers, and infections.
Y-king Biologics aims to improve the efficacy and safety of therapeutic antibodies, lowering treatment cost and frequency and ultimately enhancing patient care and access. Facilitating this is an innovative approach to engineering pH-dependent antigen-binding properties into any monoclonal antibody using an immunoglobulin scaffold.
The collaboration between DTU Bioengineering and BioInnovation Institute (BII) marks an important milestone in the journey to advance therapeutic antibodies for patients in need. The project is led by Professor Andreas Laustsen from DTU Bioengineering, Center for Antibody Technology, and Entrepreneur in Residence Rikke C. Nielsen from BII.
